Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa-Reference-Cited by-同舟云学术

Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa

Published:2022-06-09 Issue:23 Volume:386 Page:2243-2245
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Gray Glenda¹^ORCID,Collie Shirley²^ORCID,Goga Ameena¹,Garrett Nigel³,Champion Jared²,Seocharan Ishen¹,Bamford Lesley⁴,Moultrie Harry⁵,Bekker Linda-Gail⁶^ORCID

Affiliation:

1. South African Medical Research Council, Cape Town, South Africa

2. Discovery Health, Sandton, South Africa

3. Centre for the AIDS Programme of Research in South Africa, Durban, South Africa

4. National Department of Health, Pretoria, South Africa

5. National Institute for Communicable Diseases, Johannesburg, South Africa

6. University of Cape Town, Cape Town, South Africa

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMc2202061

Reference3 articles.

1. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

2. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study

3. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Causal Inference of the Effect of Vaccination on COVID-19 Disease Severity and Need for Intensive Care Unit Admission Among Hospitalized Patients in an African Setting;Cureus;2024-08-25

2. Beyond COVID-19: the promise of next-generation coronavirus vaccines;npj Viruses;2024-08-22

3. Vaccine pharmacovigilance in South Africa: successes and limitations of current approaches;Expert Opinion on Drug Safety;2024-08-08

4. Deisolation in the Healthcare Setting Following Recent COVID-19 Infection;Viruses;2024-07-15

5. Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial;Vaccine;2024-07